Karin Schulze
6 Papers
4 Citations
Karin Schulze is an academic researcher. The author has contributed to research in topics: Vaccination & Randomized controlled trial. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Murdo Ferguson,Klaus Peters,Marc Dionne,Karin Schulze,Brian Ramjattan,Peter Hillemanns,Ulrich Behre,P.V. Suryakiran,Florence Thomas,Frank Struyf +12 more
TL;DR: Investigation of the immunogenicity and safety of 2-dose schedules of the HPV-16/18 AS04-adjuvanted vaccine found that a 2D schedule could facilitate implementation of HPV vaccination programs and improve vaccine coverage and series completion rates.
111
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Klaus Peters,Marc Dionne,Ulrich Behre,Karin Schulze,Peter Hillemanns,P.V. Suryakiran,Florence Thomas,Frank Struyf +10 more
TL;DR: In conclusion, a 2D M0,6 schedule of the HPV-16/18 AS04-adjuvanted vaccine was immunogenic for up to 5 y in 9–14 y-old girls and the vaccine had a clinically acceptable safety profile in both groups.
89
O608 immune response to the hpv-16/18 as04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 3 years after vaccination
T.F. Schwarz,B. Romanowski,Klaus Peters,M. Dionne,Karin Schulze,B. Ramjattan,Peter Hillemanns,P.V. Suryakiran,Florence Thomas,Frank Struyf +9 more
TL;DR: The HPV-16/18 AS04-ADJUVANTED VACCINE ADMINISTERed as a 2-Dose or 3-DOSE SCHEDULE up to 3 years after vaccination showed promising results in women and girls with protection against cervical cancer.
6
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Klaus Peters,Marc Dionne,Karin Schulze,Brian Ramjattan,Peter Hillemanns,Grégory Catteau,Kurt Dobbelaere,Anne Schuind,Dominique Descamps +11 more
TL;DR: The results indicate that the HPV-16/18 vaccine on a 2D M0,6 schedule is immunogenic and generally well tolerated in girls 9-14 years and that the 2D schedule is likely adequate for younger females.
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Tino F. Schwarz,Marek Spaczyński,Achim Schneider,Jacek Wysocki,Andrzej Galaj,Karin Schulze,Sylviane Poncelet,Grégory Catteau,Florence Thomas,Dominique Descamps +9 more
TL;DR: The HPV-16/18 AS04-adjuvanted vaccine induces high and sustained immune responses in women aged 15-55 years, with antibody levels remaining several-fold higher than natural infection levels for at least 4 years after the first vaccine dose.